A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Not Applicable

Not yet recruiting

• Conditions: Pulmonary Hypertension
• Interventions: Drug: PF-07868489

• Registration Number: NCT07073820
• Lead Sponsor: Pfizer

Brief Summary

The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart.

This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-07
• Study First Submitted: 2025-07-09
• Study First Submitted QC: 2025-07-09
• Last Update Submitted: 2025-07-09
• Study First Posted: 2025-07-18
• Last Update Posted: 2025-07-18
• Study Start: 2025-08-24
• Primary Completion: 2029-01-08
• Study Completion: 2029-01-08

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Open Label	PF-07868489	Participants will receive subcutaneous doses of PF-07868489 every 4 weeks

Primary Outcome Measures

Name	Time	Method
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Baseline up to week 111
Number of Participants With Change From Baseline in Laboratory Tests Results	Baseline up to week 111
Number of Participants With Vital Sign Abnormalities	Baseline up to week 111

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters	Baseline up to week 111
Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration	Baseline up to week 104
Minimum Observed Plasma Trough Concentration (Cmin), as data permits	Baseline up to week 111
Incidence of Anti-Drug Antibody (ADA)	Baseline up to week 111